SuperworthEndovia Health Sciences EDVA
- Market cap
- $1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Endovia Health Sciences' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.1M+6% | $2.7M−44% | $1.5M−74% | $1M−80% | $981.9K−81% | $585.9K−78% | $438.3K−72% | $0 | n/a | n/a | n/a | n/a | |
| Cost of revenue | $3.8M+24% | $2M−40% | $1.4M−66% | $802.4K−77% | $690.8K−82% | $929.5K−53% | $43.1K−97% | $8.7K−99% | $0 | n/a | $2.4K−95% | $0 |
| Gross profit | $1.3M−27% | $733.2K−51% | $163.6K−91% | $244.4K−86% | $291K−78% | −$343.6K | $25.5K−84% | −$32.1K | $0 | n/a | $1.8K−93% | $0 |
| SG&A | $3M+12% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| −$4.3M−15% | −$3.3M−31% | −$3.3M−6% | −$3.7M−13% | −$2.7M−38% | −$6.4M+96% | −$2M−38% | −$1.6M−56% | −$9.5M+258% | n/a | n/a | n/a | |
| Interest expense | $221.5K+235% | $1.3M+4892% | $532.6K+219% | $622.1K+260% | $890.5K+302% | $1.7M+28% | $637.3K+20% | $625K+1% | $320K−64% | n/a | $889.5K+40% | $231K−63% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | −$1.7M | −$1.5M | n/a | n/a | −$979K−41% | −$2M+34% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | n/a | $0 | $0 | |
| Net income | −$5.7M+10% | −$6M+25% | −$4.7M+25% | −$5.3M−5% | −$4.7M−17% | −$9M+51% | −$3.7M−22% | −$8.5M+59% | −$9.9M+110% | −$3.2M−65% | −$2.1M−42% | −$2.1M−76% |
| −$20.80−7% | −$22.40+17% | −$16.68+4% | −$17.36−17% | −$14.20−32% | −$24.12+8% | −$7.88−53% | −$17.88+3% | −$18.04+27% | −$5.80−76% | −$1.88−76% | −$0.77−96% | |
| 267.6K+15% | 273.8K+9% | 280K+20% | 307K+17% | 326.7K+22% | 374.5K+37% | 464.3K+66% | 475K+55% | 547.9K+68% | 696.8K+86% | 1.1M+146% | 3.1M+545% |
Net income: 10 periods, Q3 FY19 to Q2 FY24: not printed by the filing, worked out from its own lines.
EPS, diluted: 18 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15: share-days: the 12-month average less the 9-month, weighted by days. Q1 FY21 and Q1 FY22: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Beverages - Non-Alcoholic nearest Endovia Health Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EDVAEndovia Health Sciences | $1M | n/m | n/a | n/m | n/m | n/m | |
| IPSTIP Strategy | $1.4M | n/m | n/a | 0.1× | +40% | n/m | |
| AMSSAmass Brands | $3.8M | n/m | n/a | n/m | n/m | n/m | |
| YHCLQR House | $3.9M | n/m | n/a | 3.2× | −50% | n/m | |
| REEDReed'S | $7M | n/m | n/a | 0.2× | −19% | −63.5% | |
| WVVIWillamette Valley Vineyards | $9.5M | n/m | 20.6× | 0.3× | −2% | −5.9% | |
| SRXHSRX Global | $21.7M | n/m | n/a | n/m | n/m | n/m | |
| BUDABuda Juice | $82.9M | n/m | n/a | n/m | n/m | n/m | |
| ZVIAZevia PBC | $99M | n/m | n/a | 0.6× | +7% | −5.3% | |
| BRCCBRC | $282.8M | n/m | n/a | 0.7× | +10% | −0.9% | |
| SUJASuja Life | $380.1M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $15.6M | n/a | 20.6× | 0.4× | +3% | −5.6% |
More on Endovia Health Sciences
Each number over time
Its groups
About
- Industry
- Beverages - Non-Alcoholic
- Sector
- Consumer Defensive
Valuation data, not investment advice. Prices as of .